#United States #Menlo Park #GRAIL #Galleri #ASCO 2026

GRAIL Prepares to Showcase Groundbreaking Cancer Detection Data at the 2026 ASCO Annual Meeting

GRAIL, Inc., a prominent player in the early cancer detection field, is set to unveil new findings from two significant clinical trials—the NHS-Galleri and PATHFINDER 2—during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 29 to June 2, 2026. The presentations promise to enrich the understanding of the Galleri® multi-cancer early detection (MCED) test, offering insights crucial for advancing cancer screening methodologies.

Overview of the NHS-Galleri Trial

The NHS-Galleri trial is particularly noteworthy, being the first and only randomized controlled study focused on an MCED test. It aims to showcase the population-level impact on late-stage cancer diagnosis by integrating annual screening via the Galleri test with the existing standard of care within the UK's National Health Service (NHS). This trial involved over 142,000 participants aged between 50 and 77, emphasizing its demographic representativeness and the depth of its findings.

The expanded results set to be shared during the ASCO gathering will elaborate on the topline findings released in February 2026. The goal of this trial is to effectively demonstrate how regular screenings with the Galleri test can improve cancer detection rates and reduce the occurrence of late-stage cancer diagnoses, a critical step in enhancing patient outcomes and survival rates.

Insights from PATHFINDER 2 Study

In addition to the NHS-Galleri trial, GRAIL will also present final results from the PATHFINDER 2 study, which comprises data from over 32,000 evaluable participants. Conducted under an FDA-approved investigational device exemption, this study represents the largest MCED interventional research project in North America involving participants without any clinical suspicion of cancer.

The PATHFINDER 2 study is pivotal in showcasing how the Galleri test can identify multiple types of cancer early, further promoting the conception that early detection significantly increases the chances for successful treatment and cures. These findings back GRAIL's assertion that their innovative approach could potentially transform existing cancer screening protocols.

The Importance of Early Cancer Detection

Dr. Josh Ofman, President of GRAIL, emphasizes the importance of early cancer detection, stating, "The goal of cancer screening is to detect cancer before it becomes advanced or spreads, when treatment options may be broader, care and cost may be less intensive, and the opportunity for cure is often greater." This statement sheds light on the dire necessity for effective screening solutions that can mitigate cancer-related mortality.

In the United States alone, over 70% of cancer deaths stem from cancers that currently lack recommended screening tests. Therefore, GRAIL's work exemplifies a significant step toward closing this gap in cancer prevention and detection.

What to Expect at ASCO 2026

The specifics of the ASCO presentations include:

• - Title: Primary results from a randomized controlled trial assessing the clinical utility of a multi-cancer early detection (MCED) test in population screening.

- Abstract Number: LBA100
- Session Title: Clinical Science Symposium - ctDNA in Clinical Practice From Detection to Clinical Decision-Making
- Date/Time: Saturday, May 30, 2026 – 812-824 am CDT

• - Title: Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.

- Abstract Number: LBA10509
- Session Title: Rapid Oral Abstract Session - Prevention, Risk Reduction, and Genetics
- Date/Time: May 31, 2026 – 945-952 am CDT

• - Title: Implementation of a multi-cancer early detection (MCED) test in a private practice adoption, performance, and repeat-testing patterns.

- Abstract Number: 10532
- Presentation Type: Poster #493
- Date/Time: June 1, 2026 – 130-430 pm CDT

These presentations will not only serve to share significant data but also underscore the potential for GRAIL’s technologies to become integral components of routine cancer screening practices.

Future Directions

GRAIL's vision of advancing cancer detection is underpinned by a commitment to leveraging cutting-edge technology and clinical research. The outcomes of the NHS-Galleri and PATHFINDER 2 trials are anticipated to provide further validation for the Galleri test's clinical utility, performance, and safety in targeted populations.

As GRAIL continues to pioneer innovations in early cancer detection, it remains steadfast in its mission to change how cancer is detected, with the ultimate aim of improving survival rates and reducing the global burden of cancer. With the impending presentations at ASCO, GRAIL seeks to enhance the dialogue around cancer screening and illuminate pathways toward earlier detection and intervention.